Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 26;188(13):3441-3458.e25.
doi: 10.1016/j.cell.2025.04.004. Epub 2025 Apr 24.

SLC7A11 is an unconventional H+ transporter in lysosomes

Affiliations
Free article

SLC7A11 is an unconventional H+ transporter in lysosomes

Nan Zhou et al. Cell. .
Free article

Abstract

Lysosomes maintain an acidic pH of 4.5-5.0, optimal for macromolecular degradation. Whereas proton influx is produced by a V-type H+ ATPase, proton efflux is mediated by a fast H+ leak through TMEM175 channels, as well as an unidentified slow pathway. A candidate screen on an orphan lysosome membrane protein (OLMP) library enabled us to discover that SLC7A11, the protein target of the ferroptosis-inducing compound erastin, mediates a slow lysosomal H+ leak through downward flux of cystine and glutamate, two H+ equivalents with uniquely large but opposite concentration gradients across lysosomal membranes. SLC7A11 deficiency or inhibition caused lysosomal over-acidification, reduced degradation, accumulation of storage materials, and ferroptosis, as well as facilitated α-synuclein aggregation in neurons. Correction of abnormal lysosomal acidity restored lysosome homeostasis and prevented ferroptosis. These studies have revealed an unconventional H+ transport conduit that is integral to lysosomal flux of protonatable metabolites to regulate lysosome function, ferroptosis, and Parkinson's disease (PD) pathology.

Keywords: acidification; cystine; ferroptosis; lysosome; pH optimum.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests H.X. is the scientific co-founder and a partial owner of Lysoway Therapeutics Inc. (Boston) and Lyso-X Therapeutics Inc. (Hangzhou).

LinkOut - more resources